.png)
ThromboGenics NV, a biopharmaceutical company developing novel medicines for back of the eye disease, announced that the protocol of the phase II CIRCLE trial evaluating multiple doses of THR-409 to induce a total posterior vitreous detachment in patients with non-proliferative diabetic retinopathy (NPDR) has been amended.
The changes will allow inclusion of patients with less severe non-proliferative diabetic retinopathy (ETDRS level 43A - 47A). This will result in a broader patient pool for the study to recruit from.
The amended study, which focuses on assessing the ability of multiple doses of THR-409 to induce a total PVD in patients with NPDR, is now expected to enroll approximately 115 patients.
ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease. The company's pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.
Thrombogenics amends protocol, circle trial evaluating, patients with npdr
1.jpg)
